Business
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company
About this update from Newcelx Ltd.
[{"type":"text","content":"\n ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) (\"NewcelX\" or \"the Company\"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board (\"SAB\").\n \n \n \n \n Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and research of neurological diseases that is home to one of the largest multidisciplinary brain and spine programs in the United States and the world's largest Phase 0 clinical trials program advancing innovative neurotherapeutics Link. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS) and has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures Link.\n In his role on the SAB of NewcelX, Prof. Shefner will provide strategic guidance on the Company's programs in ALS, including the clinical development of AstroRx®, and will support the integration of neuromuscular and neurodegenerative disease expertise into the Company's broader platform of cell therapy and neuroscience innovation.\n \"We are very pleased to welcome Prof. Shefner to our Scientific Advisory Board,\" said Ronen Twito, Executive Chairman & CEO of NewcelX. \"His leadership in ALS research and trial methodology strengthens our ability to bring advanced therapies to patients living with this devastating disease. His appointment underscores our commitment to scientific excellence and rigorous clinical execution.\"\n \n Prof. Shefner commented: \"It is a privilege to join NewcelX's SAB at this pivotal moment. I believe the Company's integrated approach—combining cell therapy and neuroscience—has significant potential to address ALS and other neurodegenerative diseases.\"\n \n About NewcelX Ltd.\n NewcelX Ltd. (Nasdaq: NCEL) is a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform merges advanced s...